Health
WestGene Biopharma Presents Groundbreaking mRNA Vaccine Data at ESMO 2024
BARCELONA, Spain, Sept. 16, 2024 /PRNewswire/ -- WestGene Biopharma, a leading innovator in mRNA therapeutics, presented the latest clinical data for its EBV-positive tumour mRNA vaccine, WGc-043, during a mini-oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. ...
2024-09-17 00:01
667
TraceLink Co-Founder and SVP of Supply Network Products Lucy Deus Named Recipient of 2024 Women in Supply Chain Award
Deus was recognized in the Trailblazers category, which honors female leaders who continue to pave the way for future women in logistics BOSTON, Sept. 16, 2024 /PRNewswire/ -- TraceLink, the only no-code platform for intelligent orchestration of end-to-end supply chains, proudly announces thatLu...
2024-09-16 23:34
801
Sirtex Medical Announces Certification of SIR-Spheres® Y-90 Resin Microspheres According to Medical Device Regulation (EU) 2017/745 and European Launch of the Innovative SIROS™ Delivery System
Sirtex brings an innovative liver cancer treatment delivery system to Europe, enhancing options for physicians and their patients. WOBURN, Mass., Sept. 16, 2024 /PRNewswire/ -- Sirtex Medical ("Sirtex"), a leading manufacturer of interventional treatment solutions, today announced that it has re...
2024-09-16 21:00
824
Argon Medical Launches CLEANER Vac™ Thrombectomy System to Remove Blood Clot in the Peripheral Venous Vasculature
PLANO, Texas, Sept. 16, 2024 /PRNewswire/ -- Argon Medical Devices, a leading provider of medical device solutions for Interventional Radiology, Vascular Surgery, Interventional Cardiology, and Oncology procedures, announced the launch of the CLEANER Vac™ Thrombectomy System for the removal of bl...
2024-09-16 20:47
794
Concord Medical Announces Obtaining Large Medical Equipment Procurement License for Its Proton Therapy Equipment
BEIJING, Sept. 16, 2024 /PRNewswire/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), a healthcare provider specialized in cancer treatment, research, education and prevention inChina, today announced that Guangzhou Concord Cancer Center ("Guangzhou H...
2024-09-16 20:00
1189
Vazyme Leads Life Science Innovation, Boosting Research Breakthroughs in mIDH1 Cancer Treatment
NANJING, China, Sept. 16, 2024 /PRNewswire/ -- Vazyme (688105.SH), a leading life science technology company, significantly contributed to groundbreaking research published in Science Magazine through its innovative products. The study, which focuses on how mutant IDH1 inhibition activates tumor ...
2024-09-16 19:00
1030
Antennova Releases Latest Data of CD73 Inhibitor ATN-037, including a DCR of 89.5%, in a Mini Oral at ESMO Congress 2024
* In patients with non-small cell lung cancer (NSCLC) or melanoma who had acquired resistance to checkpoint inhibitors (CPIs), ATN-037 in combination with KEYTRUDA®(pembrolizumab) demonstrated an overall response rate (ORR) of 21.1% and a disease control rate (DCR) of 89.5%. * Data from the...
2024-09-16 18:00
1216
Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024
HONG KONG, Sept. 16, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso (9926.HK) published the phase 2 results from its ivonescimab in combination with chemotherapy as a first-line (1L) treatment for triple-negative breast cancer (TNBC). The prelimina...
2024-09-16 15:35
1493
Alphamab Oncology Presented the Latest Clinical Data from Two Studies on Anti-HER2 Bispecific ADC JSKN003 at the ESMO Congress 2024
SUZHOU, China, Sept. 16, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the latest clinical data from two studies on anti-HER2 bispecific antibody-drug conjugate (ADC) JSKN003 were presented at the 2024 European Society for Medical Oncology Congress (ESMO Congress 202...
2024-09-16 13:03
1288
"Transfersome Gel" a New Solution for Hypertrophic Scars Chula Pharmacy's Latest Innovation
BANGKOK, Sept. 16, 2024 /PRNewswire/ -- Lecturers at the Faculty of
Pharmaceutical Sciences,Chulalongkorn University
2024-09-16 10:00
1226
ESMO 2024 - ImmVira Unveils Clinical Results of Intravesical MVR-T3011 for High-Risk BCG-Failure NMIBC Patients
SHENZHEN, China, Sept. 15, 2024 /PRNewswire/ -- ImmVira announced the latest clinical results for its lead oncolytic virus product, MVR-T3011, via intravesical administration in patients with high-risk BCG-failure non-muscle invasive bladder cancer (NMIBC). The results were published through post...
2024-09-15 17:53
2622
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024
Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso released the Phase 2 clinical results of its internally developed PD-1/VEGF bispecific antibody, ivonescimab, with or...
2024-09-15 15:10
2499
Dialogue with CGT Leaders! You Are Invited to Join the "2024 GenScript Biotech Global Forum•London" to Discuss the Future Together
PISCATAWAY, N.J., Sept. 14, 2024 /PRNewswire/ -- The year 2024 marks a milestone year for continuous advancements in Cell and Gene Therapy (CGT). The global launch of Amtagvi, a Tumor-Infiltrating Lymphocyte (TIL) therapy, has ushered in a new era for solid tumor treatment using cell therapy. PM3...
2024-09-15 06:53
1558
Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration
NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U...
2024-09-14 19:43
3136
Gan & Lee Pharmaceuticals Presented Two Positive Clinical Results of Once-weekly Insulin GZR4 at the 60th Annual Meeting of the European Association for the Study of Diabetes (EASD 2024)
* In Phase Ia clinical study, GZR4 demonstrated favorable safety and tolerability profiles in healthy subjects, maintaining a stable glucose-lowering effect for up to one week with a single administration. * In Phase Ib clinical study, patients with Type 2 diabetes mellitus (T2DM) receiving s...
2024-09-14 19:00
3503
Harbour BioMed Announces the Latest Clinical Data on the First-in-Class Fully Human Anti-B7H7/HHLA2 Monoclonal Antibody HBM1020 at the ESMO Congress 2024
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development, and commercialization of novel antibody therapeutics focusing on oncology and immuno...
2024-09-14 16:06
3154
NiceTop™️ Unveils New Hair Growth Supplement Amid Product Line Expansion
PLEASANTON, Calif., Sept. 13, 2024 /PRNewswire/ -- NiceTop™️, a U.S.-based anti-aging research team, has launched a new hair growth supplement, marking its latest foray into the personal care and nutrition market. The NiceTop™️ brand team, founded in 2012, announced the release of NiceTop™️ Hair...
2024-09-14 12:21
944
Live from ESMO 2024 | Ascentage Pharma Releases Latest Data Showing Sustained Clinical Efficacy of Olverembatinib in SDH-Deficient GIST during a Mini Oral Presentation
ROCKVILLE, Md. and SUZHOU, China, Sept. 14, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that it has released t...
2024-09-14 08:18
3252
MediLink presents YL201 (B7H3 ADC) at ESMO 2024, with over 6-months PFS in SCLC, and showing pan-tumor benefits
* The first publication of clinical data for YL201, featured in an oral presentation at ESMO 2024. * Encouraging antitumor activity of YL201 in multiple solid tumor types, including SCLC, NPC, and wild-type NSCLC, from Phase I escalation and expansion results. * In extensive-stage SCLC pati...
2024-09-14 01:00
2679
111 Inc. Announces Its Co-founders' Strategic Share Purchase and Highlights Continued Growth and Innovation
SHANGHAI, Sept. 13, 2024 /PRNewswire/ -- 111, Inc. ("111" or the "Company") (NASDAQ: YI), a leading tech-enabled healthcare platform company committed to reshaping the value chain of healthcare industry by digitally empowering the upstream and downstream inChina, today was informed by co-founders...
2024-09-13 19:30
2643
Week's Top Stories
Most Reposted
Singapore-based video streaming provider teams up with renowned celebrity platform to provide much-needed boost for brands
[Picked up by 323 media titles]
2024-09-13 17:12
HS HYOSUNG Unveils New CI and Vision, Embracing "Star" and "Tree" Symbolism
[Picked up by 313 media titles]
2024-09-11 20:27FETC International's MD Dr. Y.C. Chang Honored with the "Master Entrepreneur Award" at APEA 2024
[Picked up by 307 media titles]
2024-09-16 11:50
VinCSS, A Vietnamese Startup, Becomes the World's First Company to Secure FIDO Device Onboarding (FDO) Certificates
[Picked up by 298 media titles]
2024-09-11 15:20
NATIONAL ENERGY AWARDS 2024 SHOWCASES MALAYSIA'S COMMITMENT TO ENERGY MANAGEMENT, ENERGY EFFICIENCY AND RENEWABLE ENERGY SOLUTIONS
[Picked up by 287 media titles]
2024-09-13 15:00
Most Read
VinCSS, A Vietnamese Startup, Becomes the World's First Company to Secure FIDO Device Onboarding (FDO) Certificates
2024-09-11 15:20
11872
HS HYOSUNG Unveils New CI and Vision, Embracing "Star" and "Tree" Symbolism
2024-09-11 20:27
11632
Mushiny Establishes Subsidiary in Japan and Showcases New Products at LTT Expo Empowering Local Partners: Mushiny's Deep Collaboration to Revolutionize the Future of Logistics
2024-09-10 17:12
7447
NATIONAL ENERGY AWARDS 2024 SHOWCASES MALAYSIA'S COMMITMENT TO ENERGY MANAGEMENT, ENERGY EFFICIENCY AND RENEWABLE ENERGY SOLUTIONS
2024-09-13 15:00
6939
Circles and e& international mark one-year success of JV & digital telco leadership
2024-09-10 15:00
6910